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Background: Fibrin-related markers (FRM) such as fibrin monomer (FM) and D-dimer (DD) are considered useful biological mark-
ers for the diagnosis of disseminated intravascular coagulation (DIC). However, no studies on the diagnostic performance of differ-
ent FRMs have been published in Korea. The aim of this study was to evaluate the diagnostic performance of FM for DIC in com-
parison with DD.
Methods: The reference limit of FM was determined based on plasma sample data obtained from 210 control individuals. To evalu-
ate diagnostic performance, FM data from the plasma samples of 139 patients with DIC-associated diseases were obtained for DIC 
scoring. FM was measured by immunoturbidimetry using STA-LIATEST FM (Diagnostica Stago, France). Patients were classified ac-
cording to the DIC score as non-DIC, non-overt DIC, or overt DIC. ROC curve analyses were performed.
Results: The reference limit in the control individuals was determined to be 7.80 µg/mL. Patients with DIC-associated diseases were 
categorized as non-DIC (N=43), non-overt DIC (N=80), and overt DIC (N=16). ROC curve analyses showed that the diagnostic per-
formance of FM was comparable to DD in both non-overt DIC and overt DIC (P=0.596 and 0.553, respectively). In addition, FM had 
higher sensitivity, specificity, positive predictive value, and negative predictive value than DD for differentiating overt DIC from 
non-DIC. 
Conclusions: This study demonstrated that the diagnostic performance of FM for DIC was comparable to DD. FM might be more 
sensitive and more specific than DD in the diagnosis of overt DIC, but not non-overt DIC. 
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INTRODUCTION
Disseminated intravascular coagulation (DIC) is a syste-
mic thrombohemorrhagic disorder that is associated with 
hyperactivation of coagulation and secondary fibrinolysis [1]. 
It is characterized by organ failure resulting from microvas-
cular thrombosis, and bleeding resulting from the consump-
tion of platelets and coagulation factors. Until recently, there 
was no single laboratory test to confirm the diagnosis of 
DIC. However, a combination of tests in patients with DIC-
associated disease might be helpful in the diagnosis of the 
disorder. A scoring system was introduced for the diagnosis 
of overt DIC by the International Society of Thrombosis and 
Hemostasis (ISTH) in 2001 [1-3]. A score of 5 or greater in-
dicates a diagnosis of overt DIC [2, 3]. The components of 
the scoring system include a decreased platelet count, pro-
longation of prothrombin time (PT), increased fibrin-related 
markers (FRMs), and decreased fibrinogen [1-3]. 
FRMs include D-dimer (DD), fibrin degradation product 
(FDP), and fibrin monomer (FM). DD is produced by sec-
ondary fibrinolysis of cross-bound fibrin in the post-throm-
botic state. In contrast, FM is produced by the release of fi-
brinopeptide A from fibrinogen by thrombin in a hyperco-
agulable state. Therefore, DD could be considered a post-
thrombotic marker while FM could be considered an im-
pending thrombotic marker [4, 5]. Although some studies 
showed advantages of FM over DD for the diagnosis or 144     www.kjlm.org
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prognostication of DIC [5-8], data for evaluating the diag-
nostic performance of different types of FRMs is limited. In 
addition, there were no defined cut-offs of FRMs for the di-
agnosis of DIC. For this reason, the present study was per-
formed to evaluate the diagnostic performance of FM for 
DIC in comparison with DD. 
MATERIALS AND METHODS
1. Subjects
To establish a reference limit for FM, plasma samples from 
210 control subjects were obtained. They were adult individ-
uals who visited our institute for routine health check-ups 
and they had normal results in blood tests, including coagu-
lation screening tests. Those with autoimmune diseases, 
chronic liver diseases, or thrombosis, and those on medica-
tion were excluded.
To evaluate the diagnostic performance of FRMs for DIC 
scoring, FM data from plasma samples were obtained from 
139 patients with DIC-associated diseases. According to the 
DIC scoring system [1-3, 9] (Table 1), the patients were 
classified into 3 groups as follows: Group 1 without DIC 
(overt DIC score and non-overt DIC score was zero), Group 
2 with non-overt DIC (overt DIC score range, 1-4 points 
and non-overt DIC score was 1 point or higher), and Group 
3 with overt DIC (overt DIC score was 5 points or higher). 
2. Laboratory analyses
All blood samples for coagulation tests were collected 
into tubes containing 3.2% sodium citrate and were proces-
sed within 4 hours after collection. Aliquots of plasma sam-
ples were prepared and frozen until the determination of 
FM. Coagulation tests for DIC scoring were performed us-
ing the following reagents (STA-NEOPLASTINE CI PLUS 
for PT, STA-PTT for activated partial thromboplastin time 
[aPTT], STA-FIBRINOGEN for fibrinogen, STA-STA-
CHROM AT III for antithrombin [AT], STA-STACHROM 
PROTEIN C for protein C [PC], STA-DEFICIENT V and 
VII for coagulation factor V and VII, respectively, STA-LI-
ATEST D-DI for DD, and STA-LIATEST for FM). FDP was 
measured semi-quantitatively by latex agglutination (FDP 
PLASMA), and DD and FM were measured by immuno-
turbidimetric assays. All analyses were performed on a 
STA-R Evolution coagulation instrument (Diagnostica St-
ago, Asnieres, France).
3. Statistical analysis
To determine the reference limit of FM in the control po-
pulation, we first checked for the normality of the data us-
ing the D’Agostino-Pearson test and eliminated outliers us-
ing the D/R ratio rule by Dixon. Hemostatic parameters 
among the 3 groups were compared by 1-way ANOVA or 
the Kruskal-Wallis test. The correlation between the DIC 
score and the levels of FRMs was analyzed, and ROC curve 
analysis was performed to compare the diagnostic perfor-
mance. According to the cut-offs of FRMs from the ROC 
curve, sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV), and the odds ratio were 
calculated. A P value of less than 0.05 was considered statis-
tically significant. All statistical analyses were performed 
using MedCalc software (Mariakerke, Belgium).
RESULTS
1. Reference limit of FM
The plasma levels of FM in the 210 control subjects ranged 
from 1.64 to 9.66 µg/mL (median, 4.03 µg/mL). The data did 
not follow a Gaussian distribution. Therefore, the cut-off 
level was determined to be 7.80 µg/mL using the right-side 
95th percentile. 
2. Comparison of hemostatic parameters for the diagnosis
  of DIC in 3 groups
Among the 139 study patients, 43 were classified into 
Group 1 (without DIC), 80 into Group 2 (with non-overt 
DIC), and 16 patients into Group 3 (with overt DIC). Ma-
lignancies (35%), vascular diseases (29%), and infections 
(20%) accounted for the majority of underlying diseases in 
all patients. There were no differences among 3 groups in 
the distribution of underlying diseases. All hemostatic pa-
rameters differed significantly among the 3 groups (Table 2). 
The values of each parameter in Group 3 were significantly 
Table 1. Scoring system for the diagnosis of disseminated intravascular co-
agulation [1-3, 9, 10]
Overt DIC
† Non-overt DIC
†
Associated diseases  - No (0), Yes (2) 
Platelet count (×10
3/µL) >100 (0), 50-100 (1), <50 (2)  >100 (0), <100 (1) 
PT (sec) <17 (0), 17-20 (1), >20 (2)  <17 (0), >17 (1) 
Fibrinogen (mg/dL) >100 (0), <100 (1)  >100 (-1), <100 (1) 
D-dimer (µg/mL) Normal (0), <5 (1), >5 (2)  NL (0), Inc (1) 
Antithrombin (83-123%)*  -  NL (-1), Dec (1)
Protein C activity (80-161%)*  - NL (-1), Dec (1)
Factor V activity (81-160%)*  -  NL (-1), Dec (1)
Factor VII activity (68-149%)*  -  NL (-1), Dec (1)
*Local reference intervals; 
†Score for each parameter is in parentheses.
Abbreviations: NL, normal; Dec, decrease; Inc, increase.Park K-J, et al.  •  Diagnostic Performance of FM in DIC
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higher than in Group 2, and those in Group 2 were signifi-
cantly higher than in Group 1. The median values of DD in 
Group 1, Group 2, and Group 3 were 2.08 µg/mL, 3.19 µg/
mL, and 8.76 µg/mL, respectively (Fig. 1A; P<0.001). The 
median values of FM in Group 1, Group 2, and Group 3 
were 5.95 µg/mL, 9.65 µg/mL, and 86.61 µg/mL, respec-
tively (Fig. 1B; P<0.001). There was a statistically signifi-
cant correlation between the levels of both FM and DD and 
the DIC score (r=0.3975, P<0.0001 for FM, and r=0.4280, 
P<0.0001 for DD). DD and FM were also significantly cor-
related in Group 1 and Group 2 (r=0.5556, P<0.0001 in 
Groups 1 and 2 combined; r=0.6487, P<0.0001 in Group 1; 
and r=0.5519, P<0.0001 in Group 2). However, there was 
no significant correlation between DD and FM in Group 3 
(with overt DIC; P=0.104). Two patients in Group 3 show-
ed extremely low levels of DD (0.56 µg/mL and 1.9 µg/mL), 
while they had relatively high levels of FM (10.6 µg/mL and 
61.33 µg/mL, respectively).
3. ROC curve analysis 
On ROC curve analyses, the diagnostic performance of 
FM and DD were similar in all 3 groups (Fig. 2, P=0.596 in 
Group 2, and P=0.553 in Group 3). To discriminate Group 
3 from Group 1, the values with the largest area under the 
curve (AUC) were set as the cut-offs for DD and FM (3.92 
µg/mL and 9.95 µg/mL, respectively). Below these cut-offs, 
FM had a higher sensitivity, specificity, PPV, and NPV than 
DD for differentiating overt DIC from non-DIC (Table 3). 
To discriminate Group 2 from Group 1, the cut-offs for DD 
and FM were 2.2 µg/mL and 7.80 µg/mL, respectively. DD 
had a higher sensitivity, NPV, and odds ratio than FM for 
differentiating non-overt DIC from non-DIC (Table 3).
Table 3. Cut-off values for fibrin-related markers
Cut-off  Sensitivity Specificity PPV NPV Odds ratio (95% CI)
I. Group 1 vs. Group 3 (Non-DIC vs. Overt DIC) 
   DD (µg/dL) 3.92*  81.20  60.00  29.09  66.67  20.67 (4.11-103.80)
   FM (µg/dL) 9.95*  93.75  72.09  55.56  91.18  12.92 (3.16-52.77)
II. Group 1 vs. Group 2 (Non-DIC vs. Non-overt DIC) 
   DD (µg/dL) 2.20*  70.00  53.49  70.00  53.49  2.68 (1.25-5.78)
   FM (µg/dL) 7.80
† 51.00 62.79 73.30  42.90 2.06 (0.97-4.41)
*Values with the largest area under the curve (AUC); 
†Upper reference limit of FM.
Abbreviations: PPV, positive predictive value; NPV, negative predictive value; CI, con-
fidence interval; DIC, disseminated intravascular coagulation; DD, D-dimer; FM, fibrin 
monomer.
Table 2. Comparison of coagulation parameters among the 3 groups
Group 1 (N=43) Group 2 (N=80) Group 3 (N=16) P value
Platelets
  (×10
3/µL)
220.0 (184-258) 75.5 (44-117) 40.5 (35.5-66.5) <0.001*
PT (sec) 13.5 (12.9-13.9) 16.3 (14.7-17.8) 22.2 (20.2-26.5) <0.0001*
Fibrinogen 
  (mg/dL)
372 (271-566) 358 (254-451) 165.5 (94-207) <0.001*
DD (µg/dL) 2.08 (0.89-4.34) 3.19 (1.62-8.41) 8.76 (4.45-35.96) <0.001*
FM (µg/dL) 5.95 (4.27-10.76) 9.65 (5.32-54.63) 86.61 (43.64-145.99) <0.001
†
AT (%)  100 (92-109.5) 71.0 (49.5-83.5) 45.5 (30.0-60.5) <0.001
†
Factor V (%) 80 (64.5-110.5) 66.5 (46.5-87.5) 25.5 (7.5-36) <0.001
†
Factor VII (%) 116 (88.25-129.75) 61.5 (47-82) 30.5 (20-44) <0.001
†
Protein C (%) 102 (89-116.25) 53.5 (39-67) 32 (22-44.5) <0.001
†
*By Kruskal-Wallis test; 
†By 1-way analysis of variance.
The data shown are the median (25p-75p).
Abbreviations: DD, D-dimer; FM, fibrin monomer; AT, antithrombin.
Fig. 1. Box plots of the plasma concentration of D-dimer (DD) (A) and fibrin monomer (FM) (B) in the 3 Groups. Data are expressed as median ±2SD. The statisti-
cal significance between the 2 groups was determined by 1-way analysis of variance.
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DISCUSSION
Hypercoagulation and secondary fibrinolysis are the ma-
jor pathologic mechanisms in DIC. Laboratory data based 
on the clinical condition might be critical for the diagnosis 
of DIC. Among the coagulation markers (PT, platelets, fi-
brinogen, FRM) in the DIC scoring system, FRMs such as 
FM and DD best reflect the underlying pathology of DIC. 
Because the measurement of FRMs has not been standard-
ized, local cut-off values remain to be defined for the appli-
cation of the ISTH DIC scoring system. For the diagnosis of 
DIC, DD was very sensitive but not specific. However, little 
is known about the diagnostic performance of FM in Ko-
rean patients with DIC. 
The present study established a reference limit for FM in 
healthy individuals and evaluated the diagnostic perfor-
mance of FM in patients with DIC-associated diseases. We 
established the cut-off for FM in 210 healthy individuals as 
7.80 µg/mL. The measurement of FM is based on immuno-
turbidimetry, which might be affected by interference from 
hemolysis, bilirubinemia, and lipidemia. We excluded sam-
ples with abnormal routine laboratory findings. Okajima et 
al. [10] reported that the level of FM in 116 healthy volun-
teers was less than 6.6 µg/mL using an ELISA method. Ha-
mano et al. [11] defined 6.1 µg/mL of FM as the clinical 
baseline using a latex immunoturbidimetric assay. 
In our study, a comparison of the ROC curves of FM and 
DD showed that FM was comparable to DD as a marker for 
the diagnosis of both non-overt DIC and overt DIC. Previ-
ous studies showed some controversial data [6, 12]. Accord-
ing to Dempfle et al. [6], FM was better indicator than DD 
for the early diagnosis of DIC and its prognosis. In contrast, 
large prospective studies by multiple institutions showed 
that FM was not a useful marker for the differentiation of 
“pre-DIC” from “not-DIC” [12]. By the ISTH, “pre-DIC” 
was defined as the state within a week before the onset of 
DIC, while “non-overt DIC” was defined as the state with 
hemostatic dysfunction that is compensated [3]. We hypoth-
esized that FM might be a more useful marker for detection 
of the early phase of non-overt DIC with compensation. The 
level of FM in Group 2 with non-overt DIC was significantly 
higher than that in Group 1 without DIC, and was lower 
than that in Group 3 with overt DIC. Differences in DD 
were also observed among the 3 Groups. However, compari-
son of ROC curves for FM and DD in the diagnosis of non-
overt DIC showed that FM was not a better indicator than 
DD. Theoretically, FM would be produced earlier than DD 
in a hypercoagulable state, while DD would be produced af-
ter thrombosis and fibrinolysis. Therefore, increased levels 
of FM without an increase in DD might enhance the diag-
nostic power of FM. In the present study, there were 2 cases 
showing an increase in FM with no increase in DD despite 
the diagnosis of overt DIC. This suggested that for the diag-
nosis of overt DIC, FM is more sensitive than DD; however, 
there was no difference between the ROC curves of DD and 
FM. Assuming that the presence of heparin might influence 
thrombin, which in turn might influence the formation of 
FM, we investigated the history of anticoagulation, and did 
not find any differences among the 3 Groups.
In the present study, we defined cut-offs for the FRMs 
Fig. 2. ROC curves of D-dimer (DD) and fibrin monomer (FM) for the diagnosis of disseminated intravascular coagulation (DIC); (A) In Group 2 (non-overt DIC), the 
area under the curve (AUC) of DD and FM were 0.638 and 0.610, respectively (P=0.596). (B) In Group 3 (overt DIC), the AUC of DD and FM were 0.819 and 0.858, 
respectively (P=0.553).
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based on the values with the largest AUC in ROC curves 
and the reference limit in the control population. Using the 
suggested cut-offs, FM showed lower sensitivity than DD in 
patients with non-overt DIC, and higher sensitivity in pa-
tients with overt DIC. DD might be obtained from both in-
travascular coagulation and extravascular sources such as 
trauma and local inflammation, while FM might result 
from only intravascular sources [6]. Therefore, FM might 
have higher sensitivity for the diagnosis of overt DIC. 
The present study had some limitations. First, the number 
of the patients was very small, especially the number of pa-
tients with overt DIC. The magnitude of FM elevation 
might be influenced by other factors such as medications or 
the nature of underlying diseases. Therefore, some patients 
with non-overt DIC had levels of FM that were more ele-
vated than in patients with overt-DIC. Second, we could not 
investigate the levels of FM at the state of pre-DIC in the 
present study. By definition, pre-DIC might reflect the early 
phase of DIC more than non-overt DIC. Lastly, we would 
like discuss the clinical utility of AT, PC, and factor V and 
factor VII for non-overt DIC included in this study. The 
clinical utility of these biomarkers in non-overt DIC is still 
under investigation [2, 3, 9, 13, 14]. In addition, these tests 
are typically not available as stat tests, as is the case at the 
authors’ institution, which also limits their clinical utility. 
In summary, we investigated the reference limit of FM in 
healthy adults and evaluated the diagnostic performance of 
FM in terms of the sensitivity, specificity, PPV, NPV, and 
AUC for the diagnosis of DIC. FM had performance com-
parable to DD for the diagnosis of DIC. 
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